The recent finding that "biological age" tests don't actually track health the way we've been told should alarm us. But not for the reason you might think.
Most coverage treats this as a simple scientific correction: researchers looked at the data more carefully and discovered the tests don't work as advertised. Case closed. Move on to the next wellness trend.
That's the wrong frame. This is better understood as a signal of what comes next: a moment to ask why these tests proliferated in the first place, and what structural incentives will keep producing similar shortcuts in the years ahead.
The biological age test story reveals something uncomfortable about modern medicine. These tests gained traction because they offered something irresistible to both consumers and the companies selling them. Consumers wanted a single number that would tell them if their lifestyle choices were working. Companies wanted to sell that reassurance. The science was treated as a secondary concern.
This dynamic is going to repeat. It has to, given how the medical marketplace works.
We're in an era of genuine scientific capability. The headlines in recent months show real advances: nanofiber implants that improve survival in serious brain tumors, fish oil compounds with actual metabolic effects, refined understanding of ADHD neurobiology. These are legitimate developments that took years of careful research.
But we're also in an era where the gap between what scientists can do and what companies can sell has narrowed dangerously. Technologies that show promise in controlled settings get repackaged for consumers before the evidence solidifies. Biomarkers that correlate with outcomes in studies become diagnostic tools in marketing materials.
The incentive structure almost guarantees this happens. A pharma company or wellness startup that waits five years for comprehensive data about a new test loses market share to competitors who launch now. The first mover captures the narrative. By the time comprehensive reviews reveal limitations, as happened with biological age testing, the market has already moved on to the next thing.
Consumers bear the financial and psychological costs. They buy tests that don't deliver what they promise. More subtly, they internalize the false precision. Someone gets a "biological age" five years higher than their chronological age and makes life decisions based on unreliable information. The test fails, but the damage persists.
The research community also pays a price. When preliminary findings get commercialized before replication, it creates a perverse incentive for future research. Scientists know their work might attract venture capital and media attention if it promises something exciting. That's not an intentional conspiracy. It's just how humans respond to incentives.
What happens next? The biological age test will fade from prominence. A few companies will rebrand or quietly shutter. Consumers will shift their attention and money to the next compelling biomarker or health measurement.
And the structural problem will remain completely unaddressed.
We need better gates between promising research and consumer products. We need longer evidence-gathering periods before something gets marketed as a health tool. We need companies to carry genuine accountability when marketed tests fail independent review.
But mostly, we need to recognize that biological age tests weren't an anomaly. They were a preview.
The next version might be a genetic test, or an AI algorithm analyzing your health data, or a microbiome-based diagnostic. Whatever form it takes, the same incentives will push it into the market before the evidence fully supports the claims.
This column isn't a prediction that future medical innovations will be worthless. Many will genuinely help people. The point is simpler: the fact that we discovered biological age testing was oversold isn't a closed chapter. It's an opening argument about how we should structure the relationship between promising science and the marketplace.
Until we address that, expect many more one-off failures that are really systematic warnings.